Detroit clinical investigator Dr. Shirish Gadgeel enrolled ineligible subjects and missed required consent for genetic testing in drug trials.
What happened
FDA inspected Dr. Gadgeel's clinical site from August 5 to August 23, 2024, reviewing his conduct of three investigational drug studies. FDA found a subject was enrolled and given study drug without meeting a required inclusion criterion, another subject stayed on study drug after confirmed disease progression, and blood samples for optional genetic analysis were collected at two visits without the separate signed consent. FDA reviewed his September 13, 2024 response and said it lacked enough detail on how he would oversee study procedures.
What FDA found
A subject was enrolled and treated through at least Cycle 6 even though a required eligibility document was missing and the record showed something else.
21 CFR 312.60A subject with confirmed disease progression stayed on the investigational drug until January 3, 2022, including doses given before the sponsor approved continued dosing.
21 CFR 312.60Blood samples for optional genetic analysis were drawn at two visits before the subject signed the separate genetic consent form.
21 CFR 312.60 and 21 CFR 50.20His written corrective action plan did not explain in enough detail how he would oversee study procedures such as eligibility and consent.
What FDA wants
Within 15 business days of receiving the letter, Dr. Gadgeel must write to FDA describing the actions he has taken to prevent similar violations. FDA says failure to address the matter adequately may lead to regulatory action.
Who should pay attention
- clinical investigators and site research staff running oncology trials
- sponsors and contract research organizations relying on site protocol and consent compliance
- IRBs and research compliance offices overseeing trial sites
This is a summary. Read the original letter on fda.gov.